Drug treatment of hypertension

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7392.764/a (Published 05 April 2003) Cite this as: BMJ 2003;326:764
  1. Daniel G Hackam, chief medical resident (danielhackam@hotmail.com)
  1. Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada L8L 2X2
  2. Old Station Surgery, Ilkeston, Derbyshire DE7 8ES

    Conclusion of editorial is somewhat flawed

    EDITOR—In his analysis of the major results of the recently published antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT), Williams concludes that the key message from this trial is that what matters most is getting blood pressure controlled and that this is overwhelmingly more important than the means. 1 2

    ALLHAT showed that all blood pressure drugs were not “created” equally.2 Williams correctly points out important differences in the secondary cause specific end points between chlorthalidone and its active comparators: doxazosin (increased congestive heart failure), lisinopril (increased stroke and coronary end points), and amlodipine (increased stroke). …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription